Etoposide-Loaded Poly(Lactic-co-Glycolic Acid) Intravitreal Implants: In Vitro and In Vivo Evaluation
- 219 Downloads
Etoposide-loaded poly(lactic-co-glycolic acid) implants were developed for intravitreal application. Implants were prepared by a solvent-casting method and characterized in terms of content uniformity, morphology, drug-polymer interaction, stability, and sterility. In vitro drug release was investigated and the implant degradation was monitored by the percent of mass loss. Implants were inserted into the vitreous cavity of rabbits’ eye and the in vivo etoposide release profile was determined. Clinical examination and the Hen Egg Test-Chorioallantoic Membrane (HET-CAM) method were performed to evaluate the implant tolerance. The original chemical structure of the etoposide was preserved after incorporation in the polymeric matrix, which the drug was dispersed uniformly. In vitro, implants promoted sustained release of the drug and approximately 57% of the etoposide was released in 50 days. In vivo, devices released approximately 63% of the loaded drug in 42 days. Ophthalmic examination and HET-CAM assay revealed no evidence of toxic effects of implants. These results tend to show that etoposide-loaded implants could be potentially useful as an intraocular etoposide delivery system in the future.
KEY WORDSocular drug delivery system retinoblastoma etoposide PLGA in vivo release
The authors would like to thank Quiral Química do Brasil S.A., for the etoposide donation, and CNPq, FAPEMIG, and Brazilian Pharmacopoeia, for the financial support.
Compliance with Ethical Standards
The experiment was approved by the Ethics Committee in Animal Experimentation of the Ezequiel Dias Foundation (Protocol 030/2011).
- 6.Fernandes-Cunha GM, Rezende CMF, Mussel WN, Silva GR, Gomes ECL, Yoshida MI, et al. Anti-toxoplasma activity and impact evaluation of lyophilization, hot molding process, and gamma-irradiation techniques on CLH-PLGA intravitreal implants. J Mater Sci. 2016;27:10. https://doi.org/10.1007/s10856-015-5621-1.Google Scholar
- 7.Hande KR. Topoisomerase II inhibitors. Update Cancer Ther 2008; 3: 13–26.Google Scholar
- 14.Dhanaraju MD, Sathyamoorthy N, Sundar VD, Suresh C. Preparation of poly(epsilon-caprolactone) microspheres containing etoposide by solvent evaporation method. Asian J Pharm Sci. 2010;5:114–22.Google Scholar
- 18.U.S. Pharmacopoeia-National Formulary [USP 39 NF 34]. Volume 1. Rockville, Md: United States Pharmacopeial Convention, Inc; 2016.Google Scholar
- 19.Tian L, He H, Tang X. Stability and degradation kinetics of etoposide-loaded parenteral lipid emulsion. J Pharm Sci 2007; 96: 1719–1728.Google Scholar
- 25.Fouad H, Elsarnagawy T, Almajhdi FN, Khalil KA. Preparation and in vitro thermo mechanical characterization of electrospun PLGA nanofibers for soft and hard tissue replacement. Int J Electrochem Sci. 2013;8:2293–304.Google Scholar
- 27.Kumar P, Wasim P, Chopra M, Chhikara A. Co-delivery of vorinostat and etoposide via disulfide cross-linked biodegradable polymeric nanogels: synthesis, characterization, biodegradation, and anticancer activity. AAPS PharmSciTech. 2017;19:634–47. https://doi.org/10.1208/s12249-017-0863-5.CrossRefPubMedGoogle Scholar
- 38.Avtar R, Tandon D. A mathematical analysis of intravitreal drug transport. Trop J Pharm Res. 2008;7:867–77.Google Scholar
- 40.Mao Y, Wu Z, Yang H, Lin S, Zheng J. Measurement of intraocular concentrations of etoposide after systemic and local administration. Eye Sci. 2004;20:178–80.Google Scholar